Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells

AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy

(2015) Jingjing Wu et al.   Journal of Hematology & Oncology

Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies

(2014) Shannon L. Maude et al.   CANCER JOURNAL

Extramedullary B Lymphoblastic Leukemia/Lymphoma (B-ALL/B-LBL): A Diagnostic Challenge

(2014) Praveen Ramakrishnan Geethakumari et al.   Clinical Lymphoma Myeloma & Leukemia

New antibody approaches to lymphoma therapy

(2014) Tejas Suresh et al.   Journal of Hematology & Oncology

A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies

(2014) Caroline S Breton et al.   Journal of Hematology & Oncology

Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells

(2014) Katarzyna Urbanska et al.   Journal of Translational Medicine

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330

(2013) C. Krupka et al.   BLOOD

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML

(2013) G. S. Laszlo et al.   BLOOD

Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia

(2013) Dieter Hoelzer   CURRENT OPINION IN ONCOLOGY

Cytosine Arabinoside Promotes Cytotoxic Effect of T Cells on Leukemia Cells Mediated by Bispecific Antibody

(2013) Wei Li et al.   HUMAN GENE THERAPY

Novel agents and biomarkers for acute lymphoid leukemia

(2013) Yanmin Zhao et al.   Journal of Hematology & Oncology

Ibrutinib and novel BTK inhibitors in clinical development

(2013) Akintunde Akinleye et al.   Journal of Hematology & Oncology

Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges

(2013) Ethan Q Han et al.   Journal of Hematology & Oncology

MEK and the inhibitors: from bench to bedside

(2013) Akintunde Akinleye et al.   Journal of Hematology & Oncology

The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies

(2013) Li Shi et al.   Journal of Hematology & Oncology

A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer

(2013) James D Mellor et al.   Journal of Hematology & Oncology

STAT inhibitors for cancer therapy

(2013) Muhammad Furqan et al.   Journal of Hematology & Oncology

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

(2013) Mathias J Rummel et al.   LANCET

Impaired B-cell reconstitution in children after chemotherapy for standard or medium risk acute precursor B-lymphoblastic leukemia

(2013) Verena Wiegering et al.   LEUKEMIA & LYMPHOMA

Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses

(2012) Slava Stamova et al.   ANALYTICAL BIOCHEMISTRY

Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab

(2012) M. Klinger et al.   BLOOD

The effects of chemotherapeutic drugs on human monocyte-derived dendritic cell differentiation and antigen presentation

(2012) J. Hu et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer

(2012) D. W. Lee et al.   CLINICAL CANCER RESEARCH

Monoclonal Antibody-Based Therapies: A New Dawn in the Treatment of Acute Lymphoblastic Leukemia

(2012) Hagop Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct

(2012) M Aigner et al.   LEUKEMIA

Disulfide-stabilized diabody antiCD19/antiCD3 exceeds its parental antibody in tumor-targeting activity

(2012) Li Wei et al.   CELLULAR ONCOLOGY

Chemoimmunotherapy in acute lymphoblastic leukemia

(2011) Dieter Hoelzer et al.   BLOOD REVIEWS

Modern Therapy of Acute Lymphoblastic Leukemia

(2011) Renato Bassan et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

(2011) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Spontaneous, transient regression of B lymphoblastic leukemia in an adult patient: A variant presentation of prodromal/pre-ALL

(2011) Chaiyaporn Boonchalermvichian et al.   LEUKEMIA RESEARCH

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Adult acute lymphoblastic leukemia

(2010) Stefan Faderl et al.   CANCER

Chemoimmunotherapy

(2010) Leisha A. Emens   CANCER JOURNAL

Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia

(2010) Deborah A. Thomas et al.   JOURNAL OF CLINICAL ONCOLOGY

Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody

(2009) T Osada et al.   BRITISH JOURNAL OF CANCER

Bispecific T-Cell Engaging Antibodies for Cancer Therapy

(2009) P. A. Baeuerle et al.   CANCER RESEARCH

Cyclophosphamide Chemotherapy Sensitizes Tumor Cells to TRAIL-Dependent CD8 T Cell-Mediated Immune Attack Resulting in Suppression of Tumor Growth

(2009) Robbert G. van der Most et al.   PLoS One

CD4 T cells: fates, functions, and faults

(2008) J. Zhu et al.   BLOOD